| Expression of the HER-2/neu proto-oncogene in serous ovarian neoplasms. | neoplasm,ovarian, |
| [Overexpression of c-erbB-2 oncogene in primary ovarian cancers: incidence and prognostic significance in 243 patients]. | ovarian, |
| C-erbB-2-oncogene expression in breast carcinoma: analysis by S1 nuclease protection assay and immunohistochemistry in relation to clinical parameters. | breast, |
| Prognostic significance of immunohistochemical c-erbB-2 proto-oncogene expression and nuclear DNA content in human breast cancer. | breast, |
| HER-2/neu oncogene expression, DNA ploidy and proliferation index in breast cancer. | breast, |
| Expression of HER-2/neu oncoprotein in human breast cancer: a comparison of immunohistochemical and western blot techniques. | breast, |
| [HER-2/neu oncogene as prognostic factor in breast carcinoma]. | breast, |
| Effects of interferons on the expression of the proto-oncogene HER-2 in human ovarian carcinoma cells. | ovarian, |
| Prediction of response to adjuvant chemotherapy in premenopausal lymph node positive breast cancer patients with morphometry, DNA flow cytometry and HER-2/neu oncoprotein expression. Preliminary results. | breast, |
| c-erbB-2 oncogene expression in hepatocellular carcinoma and cholangiocarcinoma. | liver,cholangiocarcinoma, |
| Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer. | breast, |
| Expression of c-erbB-2 oncogene protein, epidermal growth factor receptor, and TGF-beta1 in human pancreatic ductal adenocarcinoma. | pancreatic, |
| c-erbB-2 oncoprotein expression related to chemoradioresistance in esophageal squamous cell carcinoma. | esophageal, |
| The coexistence of ERBB2, INT2, and CMYC oncogene amplifications and PTEN gene mutations in endometrial carcinoma. | endometrial, |
| Her-2/neu oncogene amplification and protein over-expression in interval and screen-detected breast cancers. | breast, |
| Expression of c-erbB-2 oncoprotein in different types of thyroid tumors: an immunohistochemical study. | thyroid, |
| The lack of HER-2/neu oncogene amplification in colorectal malignancies. | colorectal, |
| expression of COX-2 may be induced in serous ovarian carcinomas by loss of tumor suppressor genes such as p53 and SMAD4 and by amplification of HER-2/neu oncogene | ovarian, |
| Overexpression of Her-2/NEU in epithelial ovarian carcinoma induces vascular endothelial growth factor C by activating NF-kappa B: implications for malignant ascites formation and tumor lymphangiogenesis. | ovarian, |
| Dual fluorescence in situ hybridization in detection of HER-2 oncogene amplification in primary hepatocellular carcinoma. | liver, |